Sample pooling allows for more people to be tested quickly using fewer testing resources
MONDAY, July 20, 2020 (HealthDay News) — An emergency use authorization (EUA) has been issued for the Quest Diagnostics Quest SARS-CoV-2 real-time reverse transcription polymerase chain reaction test for use with pooled samples containing up to four individual swab specimens collected under observation, the U.S. Food and Drug Administration said Saturday.
The test is the first COVID-19 diagnostic test to be authorized for use with pooled samples.
Sample pooling is an important public health tool because it allows for more people to be tested quickly using fewer testing resources, according to the FDA.
“This EUA for sample pooling is an important step forward in getting more COVID-19 tests to more Americans more quickly while preserving testing supplies,” FDA Commissioner Stephen Hahn, M.D., said in an agency news release. “Sample pooling becomes especially important as infection rates decline and we begin testing larger portions of the population.”
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer 
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints 
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis 
U.S. Adults May Not Understand Their Risk for Vascular Disease 
Lower Cognitive Functioning During 60s Linked to Subsequent Stroke Risk 
Polypharmacy of Prescription Medications Increased for U.S. Older Adults 
Nearly 1 in 10 Older Adults Used Cannabis in the Past Year 
Lower Vertebral Bone Mineral Density Linked to Cognitive Decline 
.jpg)